Rolf Wolfgang Hartmann

Rolf Wolfgang Hartmann

Auto-generated profile, based on publicly available information

Rolf Wolfgang Hartmann

Department of Drug Design and Optimization Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) Helmholtz Centre for Infection Research (HZI) Campus E8 1 66123 Saarbrücken Germany

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2018 in Journal of the American Chemical Society
Verified
Journal Article
Open access
RSRoman Sommer
Roman Sommer
SWStefanie Wagner
Stefanie Wagner
KRKatharina Rox
Katharina Rox
AVAnnabelle Varrot
Annabelle Varrot
DHDirk Hauck
Dirk Hauck
ATAlexander Titz
Alexander Titz
The opportunistic Gram-negative bacterium Pseudomonas aeruginosa is a leading pathogen for infections of immuno-compromised patients and those suffering from cystic fibrosis. Its ability to switch from planktonic life to aggregates, forming the so-called biofilms, is a front-line mechanism of antimicrobial resistance. The bacterial carbohydrate-binding protein LecB is an integral component and necessary for biofilm formation. Here, we report a new class of drug-like low molecular weight inhibitors of the lectin LecB with nanomolar affinities and excellent receptor binding kinetics and thermodynamics. This class of glycomimetic inhibitors efficiently blocked biofilm formation of P. aeruginosa in vitro while the natural monovalent carbohydrate ligands failed. Furthermore, excellent selectivity and pharmacokinetic properties were achieved. Notably, two compounds showed good oral bioavailability and high compound concentrations in plasma and urine were achieved in vivo.

24 September 2012 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MSMichael P. Storz
Michael P. Storz
CMChristine K. Maurer
Christine K. Maurer
CZChristina Zimmer
Christina Zimmer
NWNathalie Wagner
Nathalie Wagner
CBChristian Brengel
Christian Brengel
RHRolf W. Hartmann
Rolf W. Hartmann

11 December 2013 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
CLCenbin Lu
Cenbin Lu
CMChristine K. Maurer
Christine K. Maurer
BKBenjamin Kirsch
Benjamin Kirsch
ASAnke Steinbach
Anke Steinbach
RHRolf W. Hartmann
Rolf W. Hartmann

18 April 2006 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
DSDaniela Schuster
Daniela Schuster
CLChristian Laggner
Christian Laggner
TSTheodora M. Steindl
Theodora M. Steindl
APAnja Palusczak
Anja Palusczak
RHRolf W. Hartmann
Rolf W. Hartmann
TLThierry Langer
Thierry Langer

25 September 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
RSRoman Sommer
Roman Sommer
KRKatharina Rox
Katharina Rox
SWStefanie Wagner
Stefanie Wagner
DHDirk Hauck
Dirk Hauck
SHSarah Henrikus
Sarah Henrikus
ATAlexander Titz
Alexander Titz
Biofilm formation is a key mechanism of antimicrobial resistance. We have recently reported two classes of orally bioavailable C-glycosidic inhibitors of the Pseudomonas aeruginosa lectin LecB with anti-biofilm activity. They proved efficient in target binding, were metabolically stable, non-toxic, selective and potent in inhibiting formation of bacterial biofilm. Here, we designed and synthesized 6 new carboxamides and 24 new sulfonamides for a detailed structure-activity-relationship for two clinically representative LecB variants. Sulfonamides generally showed higher inhibition compared to carboxamides which was rationalized based on crystal structure analyses. Substitutions at the thiophenesulfonamide increased binding through extensive contacts with a lipophilic protein patch. These metabolically stable compounds showed a further increase in potency towards the target and in biofilm inhibition assays. In general, we established the structure-activity relationship for these promising anti-biofilm agents and showed that modification of the sulfonamide residue bears future optimization potential.

5 July 2012 in ACS Chemical Biology
Verified
Journal Article
Closed access
TKTobias Klein
Tobias Klein
CHClaudia Henn
Claudia Henn
JJJohannes C. de Jong
Johannes C. de Jong
CZChristina Zimmer
Christina Zimmer
BKBenjamin Kirsch
Benjamin Kirsch
RHRolf W. Hartmann
Rolf W. Hartmann